Loading clinical trials...
Loading clinical trials...
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Flexible Dosing of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Conditions
Interventions
Brexpiprazole, OPC-34712
Locations
70
United States
Imperial, California, United States
Lakewood, California, United States
Long Beach, California, United States
Long Beach, California, United States
Panorama City, California, United States
Universal City, California, United States
Start Date
September 1, 2013
Primary Completion Date
March 1, 2017
Completion Date
March 1, 2017
Last Updated
November 20, 2020
NCT06159673
NCT07457138
NCT07033494
NCT07422857
NCT07214727
NCT06584357
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions